Obesity and the odds of weight gain following androgen deprivation therapy for prostate cancer - Abstract

Background: Increasing body mass index (BMI) is associated with increased risk of mortality; however, quantifying weight gain in men undergoing androgen deprivation therapy (ADT) for prostate cancer (PC) remains unexplored.

Methods: Between 1995 and 2001, 206 men were enrolled in a randomized trial evaluating the survival difference of adding 6 months of ADT to radiation therapy (RT). BMI measurements were available in 171 men comprising the study cohort. The primary endpoint was weight gain of ≥10 lbs by 6-month followup. Logistic regression analysis was performed to assess whether baseline BMI or treatment received was associated with this endpoint adjusting for known prognostic factors.

Results: By the 6-month followup, 12 men gained ≥10 lbs, of which 10 (83%) received RT + ADT and, of these, 7 (70%) were obese at randomization. Men treated with RT as compared to RT + ADT were less likely to gain ≥10 lbs (adjusted odds ratio (AOR): 0.18 (95% CI: 0.04-0.89); P = 0.04), whereas this risk increased with increasing BMI (AOR: 1.15 (95% CI: 1.01-1.31); P = 0.04).

Conclusions: Consideration should be given to avoid ADT in obese men with low- or favorable-intermediate risk PC where improved cancer control has not been observed, but shortened life expectancy from weight gain is expected.

Written by:
Braunstein LZ, Chen MH, Loffredo M, Kantoff PW, D'Amico AV.   Are you the author?
Harvard Radiation Oncology Program, Brigham and Women's Hospital, ASB-I Radiation Oncology L2, 75 Francis Street, Boston, MA 02115, USA; Department of Statistics, University of Connecticut, 215 Glenbrook Road, U-4120, Storrs, CT 06269-4120, USA; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Mailstop Dana 1230, 450 Brookline Avenue, Boston, MA 02215, USA; Department of Radiation Oncology, Dana-Farber/Brigham and Women's Hospital, ASB-I Radiation Oncology L2, 75 Francis Street, Boston, MA 02115, USA.

Reference: Prostate Cancer. 2014;2014:230812.
doi: 10.1155/2014/230812


PubMed Abstract
PMID: 24864213

UroToday.com Prostate Cancer Section